Introduction {#Sec1}
============

Neurofibromatosis type 1 (NF1), formerly known as Von Recklinghausen's disease, is an autosomal dominant inherited condition with an incidence of 1:2,500--1:3,000, and a prevalence of 1:4,000--1:5,000 \[[@CR1]\]. Clinical manifestations of NF1 involve multiple systems, including the nervous system, bone, and skin, with patients developing manifestations of hyperpigmentation and neurofibromas \[[@CR2]\]. The National Institute of Health (NIH) Consensus Development Conference have determined the diagnostic criteria for NF1, which requires two or more of the following: six or more café au lait macules; two or more cutaneous/subcutaneous neurofibromas, or one plexiform neurofibroma; axillary/groin freckling; optic glioma; two or more Lisch nodules in the eyes; bony dysplasia; and a first-degree relative with NF1 \[[@CR3]\].

Cutaneous neurofibromas can affect any part of the body and can vary in size, number, and distribution. Neurofibromas usually appear around puberty and continue to grow in size and number \[[@CR4]\]. Significant disfigurement can result from the growth of hundreds of cutaneous neurofibromas, leading to social isolation and emotional distress \[[@CR5]\].

Treatment of cutaneous neurofibromas is predominantly surgical but alternative treatments need to be considered for patients with multiple lesions often in excess of 100, in whom surgical intervention may not be possible or desirable \[[@CR6]\]. The CO~2~ laser has been shown to be effective in treating large numbers of small-to-medium sized neurofibromas with cosmetic outcomes equal to or even better than surgical excision \[[@CR2], [@CR7]\]. However, evidence for CO~2~ effectiveness, effect of treatment on patient satisfaction, and rate of recurrence post-treatment is scarce. The authors evaluated a series of patients with multiple neurofibromas that were successfully treated using CO~2~ laser treatment under general anesthetic, and assessed patient satisfaction with the treatment and rate of recurrence post-treatment.

Materials and Methods {#Sec2}
=====================

Patients {#Sec3}
--------

The authors' inclusion criteria included patients who were diagnosed with NF1, fulfilled the NIH Consensus Development Conference NF1 diagnostic criteria, had more than 100 neurofibromas of varying sizes, and were treated with CO~2~ laser treatment over the last 4 years. Seven NF1 patients satisfied these inclusion criteria and were included. Informed consent was obtained from five patients (71% response rate) for a post-treatment telephone survey.

Carbon Dioxide Laser Treatment Procedure {#Sec4}
----------------------------------------

All patients underwent test patches with the CO~2~ laser and were reviewed at 3--6 months when the results were assessed. If satisfactory, patients were then invited for CO~2~ laser treatment under general anesthetic.

The Sharplan^®^ 40 C Silktouch laser (Laser Industries Ltd., Tel Aviv, Israel) was used in its freehand continuous mode (10--20 W with rapid side-to-side hand movements) or in scanner settings (125 mm hand piece, 7--14 W, 3 mm spot) to ablate the small neurofibromas. Peripheries of larger lesions were first scored with the continuous laser beam. The incision was then extended as the neurofibroma was held with forceps and the entire dumbbell-shaped lesion was excised using the laser. Bleeding was rarely encountered and was easily controlled using the defocused laser beam or Vicryl^®^ (Johnson & Johnson, NJ, USA).

Postoperatively, antibacterial ointment (mupirocin, Bactroban^®^; Smithkline Beecham Corporation, Philadelphia, PA, USA) was applied under hydrocolloid dressings as the laser wounds healed with secondary intention. Wounds that were considered large enough for delayed secondary intention healing were sutured with Vicryl. All patients were followed up 3 and 6 months later to review the wound, scarring, and cosmetic outcome of treated neurofibroma lesions.

Data Collection {#Sec5}
---------------

Five patients completed the post-treatment telephone survey, which was conducted by the same doctor. Patients were asked to rate their satisfaction of CO~2~ laser treatment (score 0--10) and whether they would recommend CO~2~ laser treatment to other patients. Retrospective data on CO~2~ laser treatments, follow-up, and recurrence following treatment was obtained.

Results {#Sec6}
=======

Clinical Outcomes {#Sec7}
-----------------

All patients had more than 100 neurofibromas of varying sizes. The mean age of patients was 45.2 (age range 36--56) with a male/female ratio of 3:2. Four patients had truncal neurofibromas and one had treatment for neurofibromas on facial, neck, and upper limb skin. Patients received a mean of 2.2 treatment sessions (range 1--4). The mean number of lesions per patient was 114 (range 20--200 lesions). The mean follow-up period was 14.4 months (range 6--24 months). Three patients (60%) had no lesional recurrence 2 years post-CO~2~ laser treatment. Two patients (40%) had recurrence of a few of the treated lesions (≤10% of treated lesions per patient). Preoperative and postoperative photos are shown in Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}. Healing took 3--4 weeks. The wounds were erythematous for approximately 3--6 months, and matured into hypopigmented and sometimes atrophic scars. There were no significant complications. All five patients reported that treatment-induced scarring was cosmetically preferable to neurofibroma lesions. Hypopigmentation or depigmentation at treatment sites were the only reported adverse effects.Fig. 1Patient 1. Before (**a**) and 6 months after (**b**) excision of neurofibromas with the CO~2~ laserFig. 2Patient 2. Before (**a**) and 6 months after (**b**) excision of neurofibromas with the CO~2~ laserFig. 3Patient 3. Before (**a**) and 6 months after (**b**) excision of neurofibromas with the CO~2~ laser

Patient Satisfaction {#Sec8}
--------------------

The mean patient satisfaction score was 9.2 out of 10 (range 8--10). All five patients (100%) commented that they would recommend CO~2~ laser treatment to other patients with neurofibromas.

Discussion {#Sec9}
==========

Surgical excision is the standard procedure for removal of lesions, with advantages of a neat linear scar and a specimen for histology. The disadvantages are a longer procedure time and higher risk of bleeding \[[@CR6]\]. CO~2~ laser treatment is suitable for removing large numbers of neurofibromas in a short time with good cosmetic outcomes and a low complication rate \[[@CR2], [@CR8]\]. The current study confirmed that CO~2~ laser treatment under general anesthetic for hundreds of small-to-medium-sized cutaneous neurofibromas has a high patient satisfaction and recommendation rate.

Previous studies have demonstrated that CO~2~ laser treatment improved patients' self-confidence, social, and sexual lives \[[@CR2], [@CR8]\]. Algermissen et al. \[[@CR2]\] reported that the depigmented scars from laser treatment were more acceptable to patients than scars from surgical excision, a finding was echoed by patients in the current study. Previously reported physical and psychological benefits following CO~2~ laser are summarized in Table [1](#Tab1){ref-type="table"} \[[@CR2], [@CR8]\]. Patients in the current study reported high satisfaction levels, suggesting that CO~2~ laser treatment can potentially improve patients' psychological well-being.Table 1Comparison of results from the current study with the published literatureStudiesMain findingsMoreno et al. \[[@CR8]\]82% reported good level of improvement in symptoms (e.g., pain, pruritus), and social activity73% reported good level of improvement in sexual activity100% reported good level of improvement from feeling of despair73% satisfaction and recommendation rateAlgermissen et al. \[[@CR2]\]Most reported an increase in self-confidence and acceptance from the social surroundingChiang et al. (this study)9.2 mean satisfaction score (score out of 10)100% recommendation rate

To the authors' knowledge, there have been no previous reports of recurrences following CO~2~ laser treatment. The current study showed that 40% of patients had regrowth of some lesions within 2 years, but these represented ≤10% of treated lesions per patient.

The current study, however, is limited by the small number of patients. Patient skin type and skin color was not documented at the start of treatment and, hence, the authors were unable to assess the potential relationship between post-treatment pigmentary changes and skin color. There may also be a potential bias with the use of a telephone survey in assessing patient satisfaction levels. In addition, the short follow-up post-treatment in the current study may not allow the authors to fully assess the recurrence of neurofibroma lesions.

Future studies with a larger number of patients, longer follow-up period, and studies that offer comparative data of CO~2~ laser treatment with surgical treatment of cutaneous neurofibromas are needed for further clarification of the effectiveness of CO~2~ laser treatment for cutaneous neurofibromas.

Conclusion {#Sec10}
==========

The authors found that CO~2~ laser treatment for cutaneous neurofibromas is associated with a low recurrence rate, achieves a high level of patient satisfaction, and potentially offers a useful alternative to surgical excision, particularly in patients with multiple lesions.
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